Welcome to our dedicated page for Innate Pharma news (Ticker: IPHA), a resource for investors and traders seeking the latest updates and insights on Innate Pharma stock.
Innate Pharma S.A. develops clinical-stage cancer immunotherapies based on antibody engineering and target identification. Company news commonly covers its next-generation antibody therapeutics portfolio, including IPH4502, a Nectin-4 antibody-drug conjugate for solid tumors; lacutamab, an anti-KIR3DL2 antibody for cutaneous and peripheral T-cell lymphomas; monalizumab, an anti-NKG2A antibody developed with AstraZeneca for non-small cell lung cancer; and IPH5201, an anti-CD39 antibody studied in non-small cell lung cancer.
Updates also address collaborations with biopharmaceutical partners such as Sanofi and AstraZeneca, oncology conference presentations, business updates, annual meeting matters, share-count and voting-right disclosures, and annual reporting under French and U.S. public-company requirements.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.